An interactive tool from Biosimilars Forum, an industry group, uses data from Pacific Research Institute to calculate potential biosimilar savings based on 75% market share.
How much could New Jersey save with biosimilars annually? The answer is $294.2 million, if biosimilars achieve a 75% market share, according to an interactive tool developed by Biosimilars Forum using Pacific Research Institute data.
The tool can provide similar savings information for every other state in the union, including Hawaii, California, Arkansas, and Florida ($45.1 million, $1.0 billion, $148.8 million, and $960.6 million, respectively).
In total, the tool predicts annual savings of $14.08 billion annually from biosimilars. The tool bases those savings on biosimilars achieving a 75% market share in each state.
The reality is that actual biosimilar market share is well below that level for many therapeutic and supportive care categories. Only in the filgrastim category is biosimilar share above 75%—the actual share is 78%—according to Amgen’s 2021 Biosimilar Trends Report.
Trastuzumab biosimilars have achieved a 70% share in the United States, relative to the reference product (Herceptin), and bevacizumab biosimilars are close behind with 69%, relative to the originator (Avastin), according to Amgen.
Infliximab, epoetin alfa, and pegfilgrastim biosimilars all have market shares under 40% relative to their originator products.
These hurdles are acknowledged in the Biosimilars Forum interactive tool report. “Misaligned incentives have made these medicines difficult for patients to access and physicians to prescribe. The current provider reimbursement system does not financially encourage the prescribing of lower-cost biosimilars," the report notes.
Sandoz in a recent report estimated US total biosimilar savings of $2.2 billion in 2019. The company was the first to bring a biosimilar to market (Zarxio, filgrastim; 2015). The Sandoz report was in agreement with the Biosimilars Forum in estimating potential 5-year savings of $100 billion from biosimilars.
The Biosimilars Forum called upon Congress and President Joe Biden to “enact commonsense policy changes” that would spur greater use of biosimilars and “unlock these savings.”
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Stable Patient Satisfaction Found After Switching From the Humira or Biosimilar CT-P17
December 14th 2024A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.
Review Confirms Clinical Safety of Sandoz Denosumab Biosimilar vs Originator
December 11th 2024Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and clinical equivalence to reference denosumab (Prolia/Xgeva), supporting its approval and extrapolation to all approved indications.